The authors ground their argument in an ecological reframing of why fungi make these toxins in the first place. Mycotoxins emerge from specialised biosynthetic machinery, including polyketide synthases, non-ribosomal peptide synthetases and terpenoid pathways, and recent surveys have reported more than 900 new fungal metabolites, predominantly polyketides, terpenoids and peptides. Rather than evolving to poison mammals, aflatoxin production increases the fitness of Aspergillus flavus by up to 26-fold against insect herbivores while suppressing competing soil microorganisms, a trade-off that persists in natural populations. The same biosynthetic continuum yields antibiotics, antifungals and immunosuppressants, suggesting that the line between mycotoxin and pharmaceutical reflects the producer organism and the exposure context rather than any fundamental chemical mechanism. When dietary mycotoxins reach the gut, they therefore encounter a microbial community that treats them much as it treats any xenobiotic, transforming them enzymatically, binding them physically and, in some cases, releasing them back into active forms.

Microbial metabolism governs mycotoxin fate through conserved mechanisms whose relative contributions depend on the chemistry of the toxin and the composition of the microbiome. Detoxification is exemplified by the de-epoxidation of deoxynivalenol, the most prevalent Fusarium trichothecene, into the far less toxic metabolite DOM-1. Bioactivation runs in the opposite direction: zearalenone can be converted by gut bacteria into alpha-zearalenol, a compound with greater estrogenic activity than its precursor. Microbial cell walls, particularly the peptidoglycan of Lactobacillus and Bifidobacterium strains, adsorb aflatoxin B1 and reduce its free absorption in the small intestine. Meanwhile, microbial deconjugation during enterohepatic cycling can prolong systemic exposure, and masked plant-derived mycotoxins, such as deoxynivalenol-glucosides, can be hydrolysed by colonic beta-glucosidases back into their toxic aglycones in species- and site-dependent ways. The authors emphasise that mycotoxin fate is therefore shaped by microbiota-specific metabolic capacity rather than being intrinsically fixed.

Aflatoxin B1, a Group 1 human carcinogen that contaminates maize, peanuts and animal feed in warm climates, illustrates how epithelial injury intersects with microbiome-dependent immune dysfunction. Multiple microbial taxa degrade aflatoxin B1 through reductive and oxidative ring-modifying pathways that diverge fundamentally from hepatic cytochrome P450 bioactivation, including laccase-mediated oxidation from Bacillus licheniformis and Streptomyces species, F420H2-dependent reductases from mycobacteria and peroxidase-mediated degradation from Pleurotus ostreatus. These activities avoid epoxidation into the DNA-reactive aflatoxin B1-8,9-epoxide, the metabolite responsible for hepatic carcinogenicity. Yet the microbiome also amplifies aflatoxin toxicity. In mice, antibiotic-mediated microbiota depletion eliminated aflatoxin-induced splenic pyroptosis, while faecal microbiota transplantation and even sterile faecal filtrate transfer recapitulated hepatic pyroptosis, implicating gut-derived pipecolic acid and norepinephrine as causal microbial mediators that activate TLR4 and NLRP3 inflammasome signalling, driving caspase-1 activation, gasdermin D cleavage and the release of interleukin-1beta and interleukin-18.

Ochratoxin A, classified as a Group 2B possible human carcinogen and found in cereals, dried fruits, coffee, wine and cocoa, poses sustained dietary risk owing to its chemical stability, long biological half-life and renal accumulation. Microbial detoxification proceeds primarily through carboxypeptidase- and peptidase-mediated hydrolysis into the less toxic ochratoxin alpha, together with cell-wall-mediated binding. Fermented food consortia, particularly Tibetan kefir communities enriched in Lactobacillus kefiranofaciens and Kazachstania species, bind and degrade ochratoxin A through multivalent interactions involving cell wall beta-glucans, polysaccharides and peptidoglycans. In vivo, kefir intervention lowered ochratoxin burden, restored tryptophan and NAD+ homeostasis, upregulated tight junction proteins including claudin-1, occludin and ZO-1, and reduced liver enzyme levels, with metabolomics confirming glycerophospholipid rebalancing. Without such protection, ochratoxin A downregulates tight junction proteins through reactive oxygen species, calcium and myosin light chain kinase-dependent signalling, induces mitochondrial ROS and caspase-dependent apoptosis, and depletes tryptophan-metabolising taxa, weakening aryl hydrocarbon receptor signalling and regulatory T cell function while LPS translocation activates hepatic TLR4 and exacerbates inflammation.

Fumonisin B1, prevalent in maize due to Fusarium contamination, competitively inhibits ceramide synthase, disrupting de novo sphingolipid biosynthesis and driving the characteristic elevation in sphinganine-to-sphingosine ratios used as a biomarker of exposure. Gut-associated lactobacilli contribute to detoxification through esterase- and amidase-mediated hydrolysis that removes tricarballylic acid side chains to form hydrolysed fumonisin B1. Among the best-characterised bacteria, Lactobacillus pontis, L. amylovorus and L. ultunensis isolated from porcine caecum converted fumonisin B1 via surface adsorption followed by enzymatic hydrolysis, achieving up to approximately 50 percent conversion within 48 hours in vitro. However, hydrolysed fumonisin B1 retains biological activity and can sustain intestinal and hepatic injury through MAPK- and NF-kappaB-dependent pathways largely independent of sphingolipid disruption. Comparative animal studies demonstrate that both compounds compromise epithelial barrier integrity, alter gut microbial composition, reduce short-chain fatty acid production by 40 to 60 percent and disrupt hepatic metabolism, although effects are generally milder following exposure to the hydrolysed form. Antibiotic treatment eliminated 75 to 80 percent of fumonisin hepatotoxicity, while faecal microbiota transplantation reproduced hepatic injury, confirming the microbiome as a causal determinant of systemic toxicity.

The trichothecenes deoxynivalenol and T-2 toxin exert toxicity primarily through inhibition of translation and activation of ribotoxic stress pathways that phosphorylate eIF2alpha and engage MAPK and NF-kappaB cascades. Deoxynivalenol reshapes intestinal microbial communities and compromises barrier function, and these effects were partially mitigated by selected strains of Bacillus velezensis, which restored tight junction protein expression, suppressed TLR4/NF-kappaB signalling and normalised microbial composition and short-chain fatty acid profiles. Lactobacillus rhamnosus GG binds deoxynivalenol via S-layer proteins and rescues food intake in anorexia models, increasing butyrate and lowering TNF-alpha and interleukin-6. For T-2 toxin, microbiota-dependent activation of interleukin-6/Janus kinase/signal transducer and activator of transcription 1 signalling mediates splenic injury, as the phenotype was abolished by antibiotic treatment and recapitulated by faecal microbiota transplantation. Elemental nano-selenium attenuated this inflammatory response by reducing reactive oxygen species, suggesting that targeting microbiome-immune interactions may represent a viable strategy to reduce trichothecene toxicity. In contrast to aflatoxin and ochratoxin, evidence for binding-mediated sequestration of trichothecenes remains limited, indicating that biotransformation rather than adsorption is the dominant microbial mechanism influencing their toxicity.

Perhaps the most provocative implication concerns antimicrobial resistance. The authors highlight emerging evidence that deoxynivalenol exposure selectively enriches Gram-positive taxa carrying antibiotic resistance genes, particularly those associated with last-resort antibiotics such as daptomycin. Enterococcus faecalis isolated from deoxynivalenol-exposed microbiota showed extensive drug resistance, with resistance exceeding 128 micrograms per millilitre to daptomycin, vancomycin and linezolid. Deoxynivalenol-induced stress promotes genomic plasticity, enhances the co-occurrence and dissemination of resistance genes via mobile genetic elements, and increases reactive oxygen species production and membrane permeability, amplifying resistance phenotypes. Bacterial defence responses to the toxin converge with classical antibiotic resistance mechanisms, including activation of ATP-binding cassette transporters, toxin-detoxifying enzymes and stress-response proteins such as porins, glutathione S-transferases and phosphotransferases. The authors caution that deoxynivalenol is not an antimicrobial in the conventional sense but may act as a selective ecological pressure that favours resistant populations, and they note that evidence that aflatoxin, ochratoxin or zearalenone directly promote horizontal resistance gene transfer remains limited.

The authors are equally candid about the limitations of the evidence base. Most reports of mycotoxin-induced microbiota perturbation remain descriptive, with limited causal or functional resolution, and many experiments use high doses and non-human models whose relevance to real-world conditions, where exposure is usually chronic and low-dose, is uncertain. Reported microbiota responses are inconsistent, with deoxynivalenol, zearalenone and aflatoxin producing opposing shifts in Proteobacteria, Firmicutes and Bacteroidetes across experimental systems, likely reflecting differences in host biology, exposure intensity, duration and matrix composition. Results for Lactobacillus are particularly inconsistent despite its relevance in detoxification, and aflatoxin exposure can even increase Lactobacillus populations, raising mechanistic questions about whether microbial enrichment reflects adaptive detoxification, ecological resilience or selection for intrinsically resistant taxa with altered functional potential. High in vitro degradation or binding rates by probiotics do not necessarily persist in vivo because of gastric pH, transit time, competing food matrices, host metabolism and enterohepatic recirculation.

Looking ahead, Garcia-Cela and Marcon Gasperini call for a shift beyond descriptive microbiota profiling toward integrative frameworks that link microbial ecology, host physiology and metabolomic outputs. Priority areas include in vivo validation of microbial detoxification pathways, systematic comparison of in vitro and dietary exposure models, and strain-level functional characterisation to resolve inter- and intra-species variability in detoxification capacity. Multi-strain consortia, including kefir-like communities, are particularly attractive because they can couple adsorption, biodegradation and ecological competition within a single system. Engineered microbial systems could be designed to express defined detoxification enzymes or high-affinity binding modules, but their deployment will require careful evaluation of containment, regulatory approval and ecological impact. Future studies must also incorporate co-exposure scenarios, enterohepatic cycling and host-specific variables to enhance translational relevance, and mechanistic resolution of feedback loops between epithelial injury and microbial metabolic reprogramming will be essential to understand whether host-microbiome interactions amplify or constrain toxicity over time. The next generation of interventions, the authors suggest, will likely be modular, mechanism-based and tailored to the toxin, matrix and host context rather than dependent on any single probiotic solution.

Subject of Research: Microbiology / Toxicology

Article Title: Mechanistic evidence and assumptions in mycotoxin-gut interaction

Article References: Garcia-Cela, E., & Marcon Gasperini, A. (2026). Mechanistic evidence and assumptions in mycotoxin-gut interaction. Frontiers in Fungal Biology, 7, Article 1855881. https://doi.org/10.3389/ffunb.2026.1855881

Image Credits: AI Generated

DOI: 10.3389/ffunb.2026.1855881

Keywords: mycotoxins, gut microbiota, aflatoxin B1, ochratoxin A, fumonisin B1, deoxynivalenol, T-2 toxin, antimicrobial resistance, intestinal barrier, microbial detoxification, Mechanistic, evidence

The scale of exposure is far from trivial. According to the Food and Agriculture Organization of the United Nations, roughly 25 percent of global crops are contaminated with mycotoxins, although the review notes that the true figure for detectable levels may exceed 60 percent. These fungal metabolites can invade food and feed at every stage of the food chain, from field to storage, and climate change together with poor storage conditions, including elevated water activity, temperature, and relative humidity, is expected to worsen fungal colonization and toxin production. Humans encounter mycotoxins through the respiratory system, the skin, and the gastrointestinal tract, with the diet representing the primary route of long-term exposure. Cereals such as maize are frequent carriers, while nuts are especially vulnerable to aflatoxins.

What makes the new synthesis particularly compelling is the accumulating evidence that several of these toxins can cross the blood-brain barrier, the highly selective endothelial fence that normally shields the brain from circulating hazards. Once inside, they accumulate in neural tissue and attack both neurons and glial cells. The review identifies a shared arsenal of damaging mechanisms: disruption of neuronal signalling pathways, DNA damage, epigenetic modifications, impaired neurogenesis, oxidative stress, dysregulated autophagy, interference with neurotransmitter systems, mitochondrial dysfunction, and neuroinflammation. The severity of the resulting neurological outcomes depends on the dose, duration, and timing of exposure, and has been linked to cognitive impairments, learning difficulties, behavioural abnormalities, and neurodegenerative and neurodevelopmental disorders, including Alzheimer’s and Parkinson’s diseases.

Ochratoxin A emerges as one of the most thoroughly characterized brain-seeking toxins. In rat brain cell cultures, OTA disrupts the neuronal cytoskeleton, reducing heavy neurofilament expression and altering oligodendrocyte maturation by decreasing myelin basic protein and myelin oligodendrocyte glycoprotein, structural changes that threaten neuronal function and myelination. Work on the mouse subventricular zone, a key neurogenic niche, showed that OTA impairs cell viability, proliferation, and differentiation in a dose-dependent manner, while chronic exposure damaged hippocampal cells in adult mice, a finding that may underpin learning and memory deficits. In three-dimensional brain cultures, OTA disrupted the cytoskeletons of neurons and astrocytes and triggered neuroinflammation. In human astrocytes, the toxin reduces proliferation, induces cell cycle arrest, and drives apoptosis through loss of mitochondrial membrane potential, while activating the JNK1/2 and p38 stress kinases, likely via disrupted calcium signalling. In microglia, OTA provokes release of the proinflammatory cytokines IL-1β, IL-18, and CXCL8, and in zebrafish it causes locomotor impairment alongside altered oxidative stress markers such as glutathione peroxidase and glutathione-S-transferase.

Zearalenone, an oestrogenic Fusarium toxin, attacks neurons through a different route. In human neuroblastoma SH-SY5Y cells it generates reactive oxygen species, lipid peroxidation, loss of mitochondrial membrane potential, and DNA double-strand breaks, with the metabolites α-zearalenol and β-zearalenol similarly disrupting the cell cycle. ZEN also activates the mitogen-activated protein kinase signalling cascade, a conserved pathway governing proliferation, survival, and apoptosis, with ROS acting as signalling intermediates that can tip cells toward programmed death. In the nematode Caenorhabditis elegans, long-term exposure induced mitochondrial fragmentation, upregulated fission and apoptosis genes, and suppressed the DAF-16/FOXO transcription factor, a central regulator of ageing and longevity, producing an ageing-related decline. In zebrafish larvae, ZEN inhibited muscle and neural development through caspase-8-dependent apoptosis and altered expression of neuronal markers including tyrosine hydroxylase and brain-derived neurotrophic factor, confirming its capacity to derail normal neuronal function.

Fumonisin B1 takes aim at cellular metabolism itself. In rat primary astrocytes and SH-SY5Y cells, FB1 inhibits mitochondrial complex I, depressing cellular respiration, depolarizing the mitochondrial membrane, spurring ROS production, and deregulating calcium signalling. Its signature lesion, however, lies in sphingolipid metabolism: by inhibiting ceramide synthases, FB1 blocks ceramide formation, causing sphinganine and sphingosine to accumulate while complex sphingolipids dwindle, a disruption tied to apoptosis, cell cycle derangement, and membrane dysfunction. This mechanism links fumonisins to equine leukoencephalomalacia and, in humans, to neural tube defects. FB1 also renders neurons more vulnerable to glutamate-induced excitotoxicity, alters GABAergic and serotonergic systems in C. elegans with resulting behavioural deficits, and suppresses immune function by impairing dendritic cell maturation and cytokine secretion, compounding the neurological threat with immunological vulnerability.

Aflatoxin B1, described in the review as the most potent natural carcinogen known, is equally formidable in the brain. In primary microglial cells it triggers lactate dehydrogenase leakage, DNA damage markers, nuclear lysis, and release of IL-1β, IL-18, and TNF-α, activating the NLRP3 inflammasome and gasdermin D-mediated pyroptosis, an inflammatory form of cell death that fuels neuroinflammation and neuronal loss. In astrocytes it causes cell cycle arrest and mitochondrial apoptosis involving Bax, Bak, and cytochrome C, while in zebrafish embryos it inhibits Na+/K+-ATPase in brain synaptosomes, producing hyperlocomotion and suppressing neurogenesis genes. Repeated administration in rats degenerates central and peripheral nerve fibres and myelin sheaths, alters biogenic amines governing cognition and memory, and disrupts hypothalamic neuropeptide balance. The toxin’s liver-derived reactive epoxide metabolite, AFB1-8,9-epoxide, is central to this oxidative assault on neural tissue.

The trichothecene T-2 toxin and deoxynivalenol round out the roster. T-2, considered the most toxic trichothecene, dismantles the cellular redox balance, overwhelming antioxidant defences and damaging lipids, proteins, and DNA; it impairs mitochondria in mouse primary neurons and N2a cells, activates caspases 8, 9, and 3 through both intrinsic and extrinsic apoptotic routes, and suppresses the Nrf2/HO-1 antioxidant defence axis. Critically, T-2 also breaches the blood-brain barrier itself, via oxidative stress and activation of matrix metalloproteinase-9, which degrades the extracellular matrix proteins collagen, laminin, and fibronectin that hold endothelial tight junctions together, inviting immune cells into the brain. DON, meanwhile, drives mitochondrial apoptosis in PC12 and hippocampal cells through Bcl-2 family mediators and p53, induces G1 cell cycle arrest in glial and hippocampal cells, shrinks dendritic arborization, shifts neurotransmitter levels, with norepinephrine and serotonin rising as dopamine and GABA fall, and triggers autophagy through the PI3K/Akt/mTOR pathway.

The review’s authors stress that, compared with other organ systems, research on mycotoxin effects on the brain remains limited, and they call for intensified study of the toxin-neuron interface to identify new drug targets within the central nervous system. They argue that protecting the public demands a comprehensive strategy spanning regulatory measures, improved agricultural and manufacturing practices, public awareness, and sustained research collaboration, alongside urgent risk assessment and stricter legislation covering both established and emerging mycotoxins in daily diets. As contamination pressures grow with a changing climate, the message of this synthesis is stark: the fungi that colonize the world’s staple crops may be quietly shaping brain health on a global scale, and the scientific community is only beginning to map the full extent of the damage.

Subject of Research: Neurotoxicity mechanisms of food-borne mycotoxins

Article Title: A scoping review on mycotoxin-induced neurotoxicity

Article References: Abia, W. A., Foupouapouognigni, Y., Nfombouot, H. P. N., Ngoungoure, L. V. N., Ntungwe, E. N., Salah-Abbès, J. B., & Tchana, A. N. (2025). A scoping review on mycotoxin-induced neurotoxicity. Discover Toxicology, 2(1), Article 1. https://doi.org/10.1007/s44339-024-00013-7

Image Credits: AI Generated

DOI: 10.1007/s44339-024-00013-7

Keywords: mycotoxins, neurotoxicity, blood-brain barrier, aflatoxin B1, ochratoxin A, fumonisin B1, zearalenone, T-2 toxin, deoxynivalenol, oxidative stress, neuroinflammation, food safety

T-2 toxin is a trichothecene mycotoxin produced by Fusarium species, and it is far from a niche problem. According to the 2018 Biomin Global Report cited by the researchers, among 8,721 agricultural product samples from 75 countries, the average concentration of T-2 toxin was 25 micrograms per kilogram, with detection rates reaching up to 23 percent. International guidelines cap permissible daily intake at 100 nanograms per kilogram of body weight. Once ingested through contaminated food or feed, the toxin can persist in animal tissues, meat, eggs and milk, posing risks along the entire food chain and raising the possibility of serious conditions such as alimentary toxic aleukia and Kaschin-Beck disease. Previous work has linked T-2 exposure to immunotoxicity, neurotoxicity, cardiotoxicity, reproductive toxicity and nephrotoxicity, largely through its capacity to trigger oxidative stress, disrupt mitochondrial protein synthesis and provoke runaway inflammation.

To test whether lycopene could counter these effects, the team, led by Saber Y. Adam and corresponding author Demin Cai of Yangzhou University along with collaborators from several institutions in China, Sudan, Egypt and South Korea, worked with 20 male BALB/c mice, six weeks old and weighing on average 23.5 grams. The animals were randomly assigned to four groups of five: an untreated control group, a lycopene-only group receiving 100 micrograms per kilogram of body weight, a T-2 group receiving the toxin at 200 micrograms per kilogram, and a combined group given lycopene four hours after T-2 exposure. Doses were delivered in sunflower oil by oral gavage every two days for 35 days. Over the five-week course, the researchers tracked body weight, feed and water intake, collected blood and fecal samples, and analyzed gut microbial communities through 16S rRNA sequencing alongside a battery of inflammatory, oxidative and metabolic assays.

The simplest measures told a stark story. Mice exposed to T-2 toxin lost weight and ate and drank less than controls, classic hallmarks of poisoning. Lycopene supplementation largely reversed these losses, restoring body weight gains and normalizing consumption patterns. Microscopic examination of the ileum, the final stretch of the small intestine and the first major barrier the toxin encounters, revealed the structural damage behind the decline: villi, the finger-like projections that multiply the gut’s absorptive surface, were shortened and widened, and crypts were deepened in T-2-exposed animals. Mice that also received lycopene showed significantly taller villi, healthier villus-to-crypt ratios and reduced crypt depth and villus width, indicating that the carotenoid helped preserve the architecture of the intestinal lining that mycotoxins typically erode.

Deeper inside the gut, the toxin also wreaked havoc on the microbial ecosystem, and lycopene partly repaired it. Alpha-diversity indices, including Shannon, Chao1, Pielou’s evenness and Simpson measures, dropped significantly in T-2-exposed mice but rebounded after lycopene treatment. Beta-diversity analyses using principal coordinates analysis, non-metric multidimensional scaling and UPGMA clustering confirmed that the four groups harbored distinctly different microbial communities, with inter-group differences significantly exceeding intra-group variation across ANOSIM, MRPP and ADONIS tests. At the phylum level, Firmicutes rose and Bacteroidota fell with toxin exposure, while the combined treatment produced a striking enrichment of Clostridiaceae, which surged to 36.37 percent in the T-2 plus lycopene group compared with just over 4 percent of Clostridiales in controls. Linear discriminant analysis effect size profiling showed that T-2 exposure favored potentially problematic taxa such as Bacilli and Staphylococcus, whereas lycopene shifted the landscape toward groups associated with gut health, including Bifidobacterium and Ligilactobacillus in the lycopene-only animals.

The downstream products of these microbes may be the key to the protection. Gut bacteria ferment indigestible fiber into short-chain fatty acids, metabolites that fuel the intestinal lining, maintain barrier integrity, modulate immune responses and influence oxidative stress in organs from brain to kidney. In this study, fecal concentrations of hexanoic, butyric, isobutyric, isovaleric, acetic, propionic, pentanoic and heptanoic acids all fell significantly in T-2-exposed mice, consistent with the idea that toxin-driven dysbiosis cripples microbial fermentation. Lycopene treatment restored these fatty acids to levels significantly higher than those in toxin-only animals, suggesting that the carotenoid helped rehabilitate the metabolic function of the gut community, not merely its taxonomic composition.

The systemic consequences were equally striking. T-2 exposure drove significant increases in the pro-inflammatory cytokines interleukin-1 beta, interleukin-2, interleukin-4, interferon gamma, interleukin-17 and tumor necrosis factor alpha, all of which were significantly reduced by lycopene, with the notable exception of interleukin-6, which remained unchanged across all groups. The toxin also spiked plasma levels of reactive oxygen species and malondialdehyde, a marker of lipid peroxidation, while depleting the antioxidant arsenal: catalase, glutathione, adenosine triphosphate and superoxide dismutase 1 all dropped significantly in poisoned mice. Lycopene supplementation reversed each of these outcomes, lowering oxidative damage markers while restoring antioxidant defenses, a pattern consistent with the compound’s established reputation as a potent quencher of reactive species and guardian of DNA, lipids and lipoproteins.

Correlation analysis wove these threads together into a coherent mechanistic picture, though the researchers caution that the associations are exploratory and do not prove causation. After false discovery rate correction, reactive oxygen species showed a strong positive correlation with the pathobiont Helicobacter and a negative correlation with hexanoic acid, while the antioxidant enzyme SOD1 correlated positively with butyric and acetic acids and negatively with Helicobacter. Bifidobacterium tracked positively with catalase, SOD1 and butyric acid, whereas Staphylococcus was negatively associated with acetic and propionic acids, and butyric acid itself was negatively correlated with malondialdehyde. Taken together, the data suggest that lycopene’s antioxidant benefit is not a standalone biochemical effect but is mechanistically entwined with its ability to foster a healthier microbial community whose fatty acid output bolsters the host’s endogenous defenses. Butyrate in particular is known to activate the Nrf2 pathway, a master regulator of antioxidant gene expression that T-2 toxin actively suppresses.

The authors are candid about the study’s limitations. With only five animals per group, statistical power is constrained, and because T-2 toxin depressed feed and water intake, it remains unclear whether lycopene’s protective effects are direct or partly secondary to improved nutrition and overall recovery. The team notes that future work should employ larger sample sizes and pair-feeding designs to disentangle these possibilities and to validate the findings as more than hypothesis-generating observations. Even so, the convergence of evidence across gut structure, microbial ecology, fatty acid metabolism, inflammatory signaling and redox balance makes a compelling case. As mycotoxin contamination persists as an intractable problem in global agriculture, the prospect that an everyday dietary pigment, abundant in the humble tomato, could shore up the gut microbiome and its protective metabolites against one of the most dangerous trichothecenes offers an appealingly simple line of defense, one that the researchers hope can be translated into practical strategies for preventing T-2-related health problems in both animals and people.

The choice of lycopene as a protective agent builds on a growing body of literature about carotenoids and health. Unlike beta-carotene, lycopene is not converted to vitamin A in the body, yet it is one of the most efficient singlet oxygen quenchers among dietary carotenoids. Its conjugated double-bond structure allows it to neutralize reactive species and protect DNA, lipids and lipoproteins from oxidation, and it is a prominent component of the Mediterranean diet, where tomato consumption has been associated with reduced risks of cardiovascular disease and certain cancers in observational studies.

The gut-centered mechanism proposed in this study fits a broader scientific framework. Approximately 100 trillion bacteria reside in the mammalian gastrointestinal tract, with Firmicutes and Bacteroidota together accounting for more than 90 percent of the community. These microbes synthesize vitamins and amino acids, biotransform bile, and ferment indigestible fiber into short-chain fatty acids that fuel the intestinal mucosa and exert systemic effects on organs including the brain, kidneys and liver. Because SCFAs help regulate immune responses and maintain homeostasis, a toxin-induced collapse of microbial fermentation capacity would be expected to reverberate far beyond the gut wall, which is precisely the pattern the researchers observed.

The study also highlights the self-reinforcing nature of oxidative stress and inflammation. Reactive oxygen species can activate inflammatory signaling pathways such as NF-kappaB and the NLRP3 inflammasome, driving production of cytokines like TNF-alpha and interleukin-1 beta, while immune cells themselves release ROS during inflammatory responses. Breaking this cycle is a recognized therapeutic goal, and the finding that lycopene simultaneously lowered cytokine levels and restored antioxidant enzymes such as catalase, glutathione and superoxide dismutase 1 suggests it acted at multiple points in the loop.

Practically, the work points toward natural compounds as accessible candidates for mitigating mycotoxin-related diseases, complementing conventional approaches like grain screening and detoxification, though translation from mice to livestock and humans will require further validation.

Subject of Research: Protective effects of lycopene against T-2 toxin-induced systemic inflammation and oxidative stress in mice through modulation of gut microbiota and short-chain fatty acids

Article Title: Lycopene mitigates T-2 toxin-induced systemic inflammation and oxidative stress in association with gut microbiota and SCFAs regulation in mice

Article References: Adam, S. Y., Ennab, W., Zhu, C., Yuan, L., Ahmed, A. A., Essa, M. O. A., Husien, H. M., Saleh, A. A., Kim, I. H., Liu, H.-Y., & Cai, D. (2026). Lycopene mitigates T-2 toxin-induced systemic inflammation and oxidative stress in association with gut microbiota and SCFAs regulation in mice. Stress Biology, 6(1), Article 63. https://doi.org/10.1007/s44154-026-00331-3

Image Credits: AI Generated

DOI: 10.1007/s44154-026-00331-3

Keywords: lycopene, T-2 toxin, mycotoxin, oxidative stress, systemic inflammation, gut microbiota, short-chain fatty acids, BALB/c mice, intestinal morphology, cytokines, antioxidant enzymes, Fusarium